Who owns NEOGENOMICS INC (NEO)? Elite investor 13F holders

3 tracked elite investors reported holding NEOGENOMICS INC as of 2026-06-30, including D.E. Shaw, Oaktree Capital Management, GAMCO. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
D.E. ShawNEOGENOMICS INCSHARE2026-06-302026-08-14 00:00:0032021519.00 USD2194758.000000SharesreduceOriginal filing
Oaktree Capital ManagementNEOGENOMICS INCSHARE2026-06-302026-08-14 00:00:00979683.00 USD1045000.000000PrincipalreduceOriginal filing
Renaissance Technologies LLCNEOGENOMICS INCSHARE2026-06-302026-08-13 00:00:000.00 USD0.000000SharesexitedOriginal filing
GAMCONEOGENOMICS INCSHARE2026-06-302026-08-12 00:00:001459000.00 USD100000.000000SharesholdOriginal filing
Bridgewater AssociatesNEOGENOMICS INCSHARE2026-06-302026-08-14 00:00:000.00 USD0.000000SharesexitedOriginal filing
Tudor InvestmentNEOGENOMICS INCSHARE2026-06-302026-08-14 00:00:000.00 USD0.000000SharesexitedOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown